U.S., Feb. 27 -- ClinicalTrials.gov registry received information related to the study (NCT06846437) titled 'JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer' on Jan. 06.
Brief Summary: This study is designed to compare the safety and efficacy of JSKN003 versus T-DM1 in unrespectable locally advanced and/or metastatic HER2-positive breast cancer participants previously treated with trastuzumab and taxane.
Study Start Date: April 30
Study Type: INTERVENTIONAL
Condition:
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
Intervention:
DRUG: JSKN003
Administered intravenously according to protocol.
DRUG: Trastuzumab emtansine (T-DM1)
Administered intravenous...